Does RANIBIZUMAB Cause Polypoidal choroidal vasculopathy? 153 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 153 reports of Polypoidal choroidal vasculopathy have been filed in association with RANIBIZUMAB (CIMERLI). This represents 1.0% of all adverse event reports for RANIBIZUMAB.
153
Reports of Polypoidal choroidal vasculopathy with RANIBIZUMAB
1.0%
of all RANIBIZUMAB reports
0
Deaths
6
Hospitalizations
How Dangerous Is Polypoidal choroidal vasculopathy From RANIBIZUMAB?
Of the 153 reports, 6 (3.9%) required hospitalization, and 2 (1.3%) were considered life-threatening.
Is Polypoidal choroidal vasculopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RANIBIZUMAB. However, 153 reports have been filed with the FAERS database.
What Other Side Effects Does RANIBIZUMAB Cause?
Death (2,250)
Off label use (1,467)
Visual acuity reduced (1,342)
Visual impairment (1,185)
No adverse event (1,012)
Drug ineffective (831)
Blindness (760)
Vision blurred (711)
Eye pain (632)
Cerebrovascular accident (543)
What Other Drugs Cause Polypoidal choroidal vasculopathy?
Which RANIBIZUMAB Alternatives Have Lower Polypoidal choroidal vasculopathy Risk?
RANIBIZUMAB vs RANIMUSTINE
RANIBIZUMAB vs RANITIDINE
RANIBIZUMAB vs RANITIDINE\RANITIDINE
RANIBIZUMAB vs RANOLAZINE
RANIBIZUMAB vs RAPAMUNE